Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Melanoma 5Neoplasms 3Glioma 3Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 2Gliosarcoma 2Central Nervous System Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Head and Neck Neoplasms 1Ependymoma 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 73Bevacizumab 57Radiotherapy 40Radiosurgery 28Carboplatin 23Nivolumab 17Etoposide 17Cisplatin 17pembrolizumab 16Irinotecan 16Ipilimumab 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Cyclophosphamide 14Carmustine 14Pemetrexed 13Topotecan 10Surgical Procedures, Operative 10Capecitabine 10Lapatinib 9Filgrastim 9Trastuzumab 8Thalidomide 8Sunitinib 8Paclitaxel 8Lomustine 8Aminolevulinic Acid 8encorafenib 7binimetinib 7Vincristine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Brain Neoplasms × poly ICLC × Clear all
NCT01188096 2023-06-12

Poly-ICLC

Wake Forest University Health Sciences

Phase 2 Completed
23 enrolled 11 charts
CNS

Brain Neoplasms, Glioma, Neoplasms

NCT00058123 2018-08-21

Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
55 enrolled 8 charts
CNS

Astrocytoma, Brain Neoplasms, Ependymoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡